Arrowhead Reports Strong Results for Experimental Drug Targeting Complement-Related Diseases
Pasadena pharmaceutical company Arrowhead Pharmaceuticals announced promising interim results Wednesday from an early-stage clinical trial of ARO-CFB at a Boston medical conference. The Pasadena-based company presented data from its Phase 1/2a study showing the experimental therapy achieved up to 90 percent reduction in complement factor B protein levels through November 15. James Hamilton, Chief ... More »